Article

[Construction, expression and targeting therapeutic of single-chain immunotoxin against hepatocellular carcinoma].

Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an 710033, China.
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 04/2004; 12(3):148-50. pp.148-50
Source: PubMed

ABSTRACT To obtain high therapeutic effect and low toxicity single-chain immunotoxin against hepatocellular carcinoma (HCC).
Human mutant tumor necrosis factor-alpha (mTNFalpha) was linked with the 3' end of humanized single-chain Fv against HCC (hscFv25) in pGEX4T-1 vector. The anti-HCC immunotoxin was expressed in Escherichia coli and identified by western blot. The primary tumor regression trial in nude mice bearing HCC was evaluated the targeting therapeutic value of hscFv25-mTNFalpha. The tumor tissues were stained by immunohistochemical with TNFalpha antibody.
The expression of single-chain immunotoxin hscFv25-mTNFalpha was 12% of total bacteria proteins. The tumor regression trials of hscFv25-mTNFalpha showed 5/5 effective. It had 2/5 completely remission and 3/5 partly remission. The therapeutic result of hscFv25-mTNFalpha was better than that of mTNFalpha (F=8.70, 0.05). The HCC tissue treated by hscFv25-mTNFalpha expressed TNFalpha positive reaction. The positive granule mainly existed in HCC cytoplasm.
The single-chain immunotoxin hscFv25-mTNFalpha has high therapeutic effect and low toxicity. It has potentialities for clinical application.

0 0
 · 
0 Bookmarks
 · 
16 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

5/5 effective
 
Escherichia coli
 
hepatocellular carcinoma
 
hscFv25-mTNFalpha
 
Human mutant tumor necrosis factor-alpha
 
humanized single-chain Fv
 
low toxicity
 
low toxicity single-chain immunotoxin
 
mTNFalpha
 
nude mice bearing HCC
 
primary tumor regression trial
 
single-chain immunotoxin hscFv25-mTNFalpha
 
targeting therapeutic value
 
therapeutic effect
 
therapeutic result
 
TNFalpha antibody
 
TNFalpha positive reaction
 
total bacteria proteins
 
tumor regression trials
 
tumor tissues